Literature DB >> 28720429

Stable isotope-based flux studies in nonalcoholic fatty liver disease.

Arthur McCullough1, Stephen Previs2, Takhar Kasumov3.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease and is associated with the worldwide epidemics of obesity, diabetes and cardiovascular diseases. NAFLD ranges from benign fat accumulation in the liver (steatosis) to non-alcoholic steatohepatitis (NASH), and cirrhosis which can progress to hepatocellular carcinoma and liver failure. Mass spectrometry and magnetic resonance spectroscopy-coupled stable isotope-based flux studies provide new insights into the understanding of NAFLD pathogenesis and the disease progression. This review focuses mainly on the utilization of mass spectrometry-based methods for the understanding of metabolic abnormalities in the different stages of NAFLD. For example, stable isotope-based flux studies demonstrated multi-organ insulin resistance, dysregulated glucose, lipids and lipoprotein metabolism in patients with NAFLD. We also review recent developments in the stable isotope-based technologies for the study of mitochondrial dysfunction, oxidative stress and fibrogenesis in NAFLD. We highlight the limitations of current methodologies, discuss the emerging areas of research in this field, and future directions for the applications of stable isotopes to study NAFLD and its complications.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Citric acid cycle; Fatty acid oxidation; Fibrosis; NAFLD; Oxidative stress; Stable isotopes

Mesh:

Substances:

Year:  2017        PMID: 28720429      PMCID: PMC5743607          DOI: 10.1016/j.pharmthera.2017.07.008

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  102 in total

Review 1.  Proteome dynamics: revisiting turnover with a global perspective.

Authors:  Amy J Claydon; Robert Beynon
Journal:  Mol Cell Proteomics       Date:  2012-11-02       Impact factor: 5.911

2.  Quantifying gluconeogenesis during fasting.

Authors:  V Chandramouli; K Ekberg; W C Schumann; S C Kalhan; J Wahren; B R Landau
Journal:  Am J Physiol       Date:  1997-12

3.  Nonalcoholic fatty liver disease as the transducer of hepatic oversecretion of very-low-density lipoprotein-apolipoprotein B-100 in obesity.

Authors:  Dick C Chan; Gerald F Watts; SengKhee Gan; Annette T Y Wong; Esther M M Ooi; P Hugh R Barrett
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-02-11       Impact factor: 8.311

Review 4.  The many intersecting pathways underlying apolipoprotein B secretion and degradation.

Authors:  Jeffrey L Brodsky; Edward A Fisher
Journal:  Trends Endocrinol Metab       Date:  2008-08-06       Impact factor: 12.015

5.  Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity.

Authors:  Elisa Fabbrini; Faidon Magkos; B Selma Mohammed; Terri Pietka; Nada A Abumrad; Bruce W Patterson; Adewole Okunade; Samuel Klein
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-24       Impact factor: 11.205

Review 6.  Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease.

Authors:  Manoela Mota; Bubu A Banini; Sophie C Cazanave; Arun J Sanyal
Journal:  Metabolism       Date:  2016-03-03       Impact factor: 8.694

7.  Prevalence and predictive factors of non-alcoholic steatohepatitis (NASH) in morbidly obese patients undergoing bariatric surgery.

Authors:  Florence Harnois; Simon Msika; Jean-Marc Sabaté; Charlotte Mechler; Pauline Jouet; Jeanine Barge; Benoit Coffin
Journal:  Obes Surg       Date:  2006-02       Impact factor: 4.129

8.  Hepatic metabolism of free fatty acids in normal and diabetic dogs.

Authors:  L V Basso; R J Havel
Journal:  J Clin Invest       Date:  1970-03       Impact factor: 14.808

Review 9.  Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia.

Authors:  Janet D Sparks; Charles E Sparks; Khosrow Adeli
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-07-12       Impact factor: 8.311

10.  Assessment of Hepatic Mitochondrial Oxidation and Pyruvate Cycling in NAFLD by (13)C Magnetic Resonance Spectroscopy.

Authors:  Kitt Falk Petersen; Douglas E Befroy; Sylvie Dufour; Douglas L Rothman; Gerald I Shulman
Journal:  Cell Metab       Date:  2016-07-12       Impact factor: 27.287

View more
  5 in total

1.  Pyruvate-Carboxylase-Mediated Anaplerosis Promotes Antioxidant Capacity by Sustaining TCA Cycle and Redox Metabolism in Liver.

Authors:  David A Cappel; Stanisław Deja; João A G Duarte; Blanka Kucejova; Melissa Iñigo; Justin A Fletcher; Xiaorong Fu; Eric D Berglund; Tiemin Liu; Joel K Elmquist; Suntrea Hammer; Prashant Mishra; Jeffrey D Browning; Shawn C Burgess
Journal:  Cell Metab       Date:  2019-04-18       Impact factor: 27.287

2.  HDL flux is higher in patients with nonalcoholic fatty liver disease.

Authors:  Arthur McCullough; Stephen F Previs; Jaividhya Dasarathy; Kwangwon Lee; Abdullah Osme; Chunki Kim; Serguei Ilchenko; Shuhui W Lorkowski; Jonathan D Smith; Srinivasan Dasarathy; Takhar Kasumov
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-09-10       Impact factor: 4.310

Review 3.  Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests.

Authors:  Mojgan Masoodi; Amalia Gastaldelli; Tuulia Hyötyläinen; Enara Arretxe; Cristina Alonso; Melania Gaggini; Julia Brosnan; Quentin M Anstee; Oscar Millet; Pablo Ortiz; Jose M Mato; Jean-Francois Dufour; Matej Orešič
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-09-10       Impact factor: 46.802

4.  Dietary fatty acid oxidation is decreased in non-alcoholic fatty liver disease: A palmitate breath test study.

Authors:  Gihan Naguib; Nevitt Morris; Shanna Yang; Nancy Fryzek; Vanessa Haynes-Williams; Wen-Chun A Huang; Jaha Norman-Wheeler; Yaron Rotman
Journal:  Liver Int       Date:  2019-12-15       Impact factor: 8.754

5.  Childhood severe acute malnutrition is associated with metabolic changes in adulthood.

Authors:  Debbie S Thompson; Celine Bourdon; Paraskevi Massara; Michael S Boyne; Terrence E Forrester; Gerard Bryan Gonzales; Robert H J Bandsma
Journal:  JCI Insight       Date:  2020-12-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.